BRIEF published on 08/27/2025 at 13:34, 1 year ago CHEPLAPHARM Reports Stable Growth in the First Half of 2025 Pharmaceutical Industry Revenue Growth Transformation Program CHEPLAPHARM Employee Expansion
PRESS RELEASE published on 08/27/2025 at 13:29, 1 year ago CHEPLAPHARM with stable business in the first half of 2025 Cheplapharm AG reports stable business performance in the first half of 2025, with revenue up by 12% and EBITDA up by 24% compared to the second half of 2024 Financial Results Transformation Program Stability Acquisition Opportunities Cheplapharm AG
BRIEF published on 06/26/2025 at 10:36, 1 year 2 months ago CHEPLAPHARM's €750M Bond Sees High Demand and Attractive Pricing Pharmaceuticals Investor Confidence Financial Flexibility Bonds CHEPLAPHARM
PRESS RELEASE published on 06/26/2025 at 10:31, 1 year 2 months ago High Demand and Attractive Pricing: CHEPLAPHARM's New 7.125% Bond Multiple Times Oversubscribed CHEPLAPHARM successfully places €750m senior secured notes at 7.125% interest rate, enhancing financial flexibility and extending maturity profile, oversubscribed transaction Senior Secured Notes Oversubscribed Financial Flexibility CHEPLAPHARM 7.125%
BRIEF published on 06/02/2025 at 10:34, 1 year 3 months ago Sandra Schröder Joins CHEPLAPHARM as VP Scientific Pharmaceutical Regulatory Affairs Quality Management CHEPLAPHARM Sandra Schröder
PRESS RELEASE published on 06/02/2025 at 10:29, 1 year 3 months ago Sandra Schröder joins CHEPLAPHARM’S Management Team as VP Scientific Sandra Schröder appointed as VP Scientific at CHEPLAPHARM, responsible for scientific areas globally. Brings 25 years of experience from F. Hoffmann-La Roche AG Pharmaceutical Industry Management CHEPLAPHARM Sandra Schröder VP Scientific
BRIEF published on 01/02/2025 at 09:19, 1 year 8 months ago CHEPLAPHARM Appoints Tamás Szóga as VP Commercial Management Expansion CHEPLAPHARM Tamás Szóga VP Commercial Pharmaceutical Strategy
PRESS RELEASE published on 01/02/2025 at 09:14, 1 year 8 months ago CHEPLAPHARM expands Management with Tamás Szóga as VP Commercial CHEPLAPHARM expands management team by appointing Tamás Szóga as VP Commercial, responsible for strategic planning and development of Global Sales division Global Sales Strategic Planning CHEPLAPHARM Tamás Szóga VP Commercial
BRIEF published on 12/16/2024 at 08:53, 1 year 9 months ago CHEPLAPHARM Acquires Gemzar from Lilly Acquisition Oncology Eli Lilly CHEPLAPHARM Gemzar
PRESS RELEASE published on 12/16/2024 at 08:48, 1 year 9 months ago CHEPLAPHARM acquires Gemzar from Lilly CHEPLAPHARM acquires Gemzar from Lilly, expanding its oncology portfolio with a proven chemotherapeutic agent for various types of cancer Acquisition Oncology CHEPLAPHARM Chemotherapy Gemzar
Published on 09/22/2026 at 23:10, 14 minutes ago Global Atomic Announces Proposed Public Offering of Units
Published on 09/22/2026 at 22:30, 54 minutes ago Silver Spruce Receives TSXV Conditional Approval of Debt Settlement
Published on 09/22/2026 at 22:01, 1 hour 23 minutes ago Fermi and TensorWave Agree to Extend Closing Date to October 31, 2026
Published on 09/22/2026 at 21:40, 1 hour 44 minutes ago Sekur Private Data Launches Sekur.com in Portuguese in Preparation for Angola Launch
Published on 09/22/2026 at 17:00, 6 hours 24 minutes ago Leggett Dynamics Expands Asia Pacific Headquarters
Published on 09/22/2026 at 19:40, 3 hours 43 minutes ago EQS-Adhoc: Pyrum Innovations AG: Revision of the Forecast for the Financial Year 2026
Published on 09/22/2026 at 19:00, 4 hours 24 minutes ago LLB focuses on its "elevate" strategy for growth, excellence and resilience
Published on 09/22/2026 at 18:30, 4 hours 54 minutes ago Avolta partners with Hawaii’s Department of Transportation to expand airport dining at three airports
Published on 09/22/2026 at 17:45, 5 hours 39 minutes ago Carvolix submits 510(k) for TAVIPILOT Robot, advancing toward US commercial launch of Its Integrated TAVIPILOT Platform.
Published on 09/22/2026 at 17:40, 5 hours 44 minutes ago VALBIOTIS SA: Valbiotis announces positive results from the Cardio-Liver clinical study - Commercial launch of ValbiotisPRO® Foie on September 23
Published on 09/22/2026 at 18:00, 5 hours 24 minutes ago Consolidated results for the first half of 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 17:45, 5 hours 39 minutes ago Imerys-09-2026-information-share-capital-and-voting-rights-as-of-31-August-2026
Published on 09/21/2026 at 18:19, 1 day 5 hours ago Reporting on share buyback transactions carried out between September 14 and September 18, 2026
Published on 09/21/2026 at 18:01, 1 day 5 hours ago Partnership agreement signed between Manitou Group and HD Construction Equipment
